Diarrhoea on Mounjaro: Why It Happens and How to Manage It

Diarrhoea on Mounjaro is one of the most common gastrointestinal side effects reported by patients starting tirzepatide. In the SURMOUNT clinical trials, between 12 and 21 per cent of participants experienced loose or frequent stools, usually during the first few weeks of treatment or after a dose increase. While it can be uncomfortable and inconvenient, diarrhoea on Mounjaro is almost always temporary and manageable with straightforward adjustments to diet, hydration, and timing.

At CutKilo, our doctor-led weight-loss programme at 86 Harley Street monitors every patient through regular check-ins, so side effects like diarrhoea are caught early and managed proactively. This guide explains why Mounjaro causes diarrhoea, how long it typically lasts, and what you can do to reduce it.

Yes. Diarrhoea is a recognised and well-documented side effect of tirzepatide (Mounjaro). It was reported by 12 to 21 per cent of participants across the SURMOUNT-1 to SURMOUNT-4 clinical trials, compared with roughly 5 to 9 per cent of those on placebo. The Medicines and Healthcare products Regulatory Agency (MHRA) lists diarrhoea as a “very common” adverse reaction in the tirzepatide Summary of Product Characteristics.

Most cases are mild to moderate, resolve within the first few weeks of treatment, and do not require stopping the medication. If diarrhoea is severe, persistent, or accompanied by dehydration symptoms, your prescribing doctor should adjust your dose or recommend supportive treatment.

The incidence varies by dose. In SURMOUNT-2, diarrhoea was reported in 19.9 per cent of participants taking tirzepatide 10 mg and 21.5 per cent of those on 15 mg, compared with 8.9 per cent on placebo. A pooled analysis published in Diabetes, Obesity and Metabolism in 2025 examined gastrointestinal tolerability across SURMOUNT-1 through SURMOUNT-4, confirming that diarrhoea was the second most common GI side effect after nausea.

Diarrhoea on Mounjaro is generally less frequent than nausea. In most trials, nausea affected 24 to 33 per cent of participants, while diarrhoea affected 12 to 21 per cent. Both side effects were most common during the dose-escalation phase and declined once patients reached a stable maintenance dose.

Tirzepatide is a dual GIP and GLP-1 receptor agonist, and both of these hormonal pathways influence gut function in ways that can loosen stools.

GLP-1 slows gastric emptying, which is the primary mechanism behind its appetite-suppressing effect. However, GLP-1 also accelerates gallbladder contraction and bile release. When excess bile acids reach the colon before they can be properly reabsorbed, they draw water into the bowel lumen and stimulate colonic motility. A study published in Endocrinology in 2024 found that 15 to 20 per cent of patients on GLP-1 receptor agonists developed measurable bile acid malabsorption, which correlated directly with diarrhoea severity.

GIP adds a second layer of effect. It stimulates intestinal mucosal blood flow and enhances nutrient-driven fluid secretion, which can further loosen stool consistency, particularly after meals.

Additional contributing factors include shifts in the gut microbiome (the balance of bacteria in your intestines changes as eating patterns change), altered pancreatic enzyme secretion, and the body’s gradual adaptation to a new hormonal environment. These mechanisms explain why diarrhoea is most common during dose escalation and often resolves as the body adjusts.

Most patients who experience diarrhoea on Mounjaro notice it within the first one to three days after their injection, particularly during the first few weeks of treatment or immediately after a dose increase. The pattern typically follows the dose-escalation schedule: starting at 2.5 mg, then moving to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg at four-week intervals.

For the majority of patients, symptoms peak in the first week after a dose change and improve over the following two to three weeks. By the time a stable maintenance dose is reached, diarrhoea has usually resolved or become infrequent. In the SURMOUNT trials, fewer than 1 per cent of participants discontinued treatment due to diarrhoea alone.

If diarrhoea persists beyond six weeks at the same dose, this is unusual and warrants a review with your prescribing doctor. Persistent symptoms could indicate bile acid malabsorption, an unrelated gastrointestinal condition, or a need to adjust the dosing schedule.

There are several evidence-based strategies that can reduce or prevent diarrhoea while you continue your Mounjaro treatment.

Stay well hydrated. Loose stools increase fluid and electrolyte losses. Aim for at least two litres of water daily, and consider an oral rehydration solution if episodes are frequent. Our guide to dehydration on Mounjaro covers the warning signs to watch for.

Adjust your diet temporarily. Reduce high-fat, greasy, and heavily spiced foods during the dose-escalation phase. Fat stimulates bile release, which can worsen bile-acid-related diarrhoea. Focus on lean proteins, plain rice, bananas, toast, and cooked vegetables until symptoms settle.

Eat smaller, more frequent meals. Large meals place a heavier load on a digestive system that is already adapting to new hormonal signals. Five smaller meals spread through the day are better tolerated than three large ones.

Avoid sugar alcohols and artificial sweeteners. Sorbitol, xylitol, and mannitol are poorly absorbed and draw water into the bowel. Check protein bars, sugar-free sweets, and diet drinks for these ingredients.

Time your fibre intake carefully. Soluble fibre (oats, psyllium husk, cooked lentils) can help firm stools, while insoluble fibre (raw vegetables, bran) may make diarrhoea worse. Increase soluble fibre gradually and reduce insoluble fibre if symptoms flare.

Ask your doctor about a slower escalation. If diarrhoea is significantly affecting your quality of life, your prescribing doctor may extend the time at each dose from four weeks to six or eight weeks, giving your gut more time to adapt.

Most diarrhoea on Mounjaro is self-limiting, but certain warning signs require prompt medical attention.

Contact your prescribing doctor or seek medical advice if you experience more than six watery stools in 24 hours, blood or mucus in your stool, signs of dehydration such as dark urine, dizziness, rapid heartbeat, or dry mouth, a fever above 38°C alongside diarrhoea, persistent symptoms lasting more than two weeks at the same dose, or severe abdominal pain or cramping.

In rare cases, persistent diarrhoea may indicate an underlying condition unrelated to Mounjaro, such as Clostridioides difficile infection, coeliac disease, or inflammatory bowel disease. Your doctor can arrange stool tests and blood work to rule these out.

Diarrhoea on Mounjaro is common, usually mild, and almost always temporary. The dual GIP and GLP-1 mechanism that makes tirzepatide so effective for weight loss also influences bile acid cycling and gut motility, which explains why loose stools occur during dose escalation. For most patients, the symptoms settle within a few weeks. Simple strategies including adequate hydration, dietary adjustment, and a slower dose escalation can make a significant difference. If symptoms persist or worsen, your prescribing doctor can investigate further and adjust your treatment plan accordingly.

Does diarrhoea on Mounjaro mean the medication is not working? No. Diarrhoea is a side effect of how tirzepatide interacts with your digestive system, not an indicator of treatment failure. Patients who experience GI side effects achieve the same weight-loss outcomes as those who do not, according to pooled data from the SURMOUNT trials published in Diabetes, Obesity and Metabolism.

Should I take anti-diarrhoeal medication like loperamide while on Mounjaro? Loperamide (Imodium) is generally safe to use occasionally for symptomatic relief, but you should discuss this with your prescribing doctor first. Over-reliance on loperamide can mask symptoms that need clinical attention, and it may slow gut motility further when combined with a GLP-1 receptor agonist.

Can I take probiotics to help with diarrhoea on Mounjaro? There is no strong clinical evidence that probiotics prevent or treat tirzepatide-related diarrhoea specifically. However, they are unlikely to cause harm, and some patients report subjective improvement. If you want to try them, choose a well-studied strain such as Saccharomyces boulardii, which has evidence for other forms of medication-related diarrhoea.

Does the diarrhoea get worse at higher Mounjaro doses? It can flare briefly with each dose increase, but most patients find that their gut adapts more quickly at higher doses than it did during the initial escalation. The SURMOUNT-2 data showed a modest increase in diarrhoea rates at 15 mg (21.5 per cent) compared with 10 mg (19.9 per cent), but the difference was not dramatic.

Is diarrhoea more common with Mounjaro than with Ozempic? Diarrhoea rates are broadly similar between tirzepatide and semaglutide (Ozempic/Wegovy). The SURMOUNT-5 head-to-head trial found comparable gastrointestinal side-effect profiles, though individual responses vary. If you are considering switching from Ozempic to Mounjaro, your prescribing doctor can help manage the transition to minimise GI disruption.